Biogen takes aim at Alzheimer's, ALS drugs 0 23.03.2015 13:48 CNBC Biogen has seen its value quadruple to more than $100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions. Партнёры Smi24.net Все новости за 24 часа Музыкальные новости Агрегатор новостей 24СМИ
